ACCCBUZZ BLOG

The first facility on Long Island, NY to offer next-generation sequencing with point-of-care genomic testing opened this May, and brought access to state of the art medical technology to patients in 6 different counties in the region.

Explore insights from this LinkedIn Live event highlighting the crucial role of pathologists within the multidisciplinary cancer care team.

Through a series of education projects, ACCC is committed to providing the resources the multidisciplinary cancer care team will need to navigate the complex precision medicine landscape and deliver next generation cancer care.

In the era of personalized medicine, biomarker testing is a tool the oncology workforce can and should leverage to deliver next generation cancer care.

Introduced in 2021, the Cancer Patient Equity Act seeks to provide coverage of certain cancer diagnostic and laboratory tests under Medicare, Medicaid, and the Children's Health Insurance Program, and more.

State legislation across the U.S. is tackling health insurance coverage for comprehensive biomarker testing. Learn more about what's going on where you live and across the nation.

Communities around the globe recognize August 1 as World Lung Cancer Day—a day to commemorate, educate, and support individuals and families impacted by lung cancer. Read highlights on a few ACCC initiatives that are helping cancer care teams better support their patients with this disease.

Measurable residual disease (MRD) has gained traction as a compelling marker for disease status across various hematologic malignancies, including multiple myeloma. Learn how MRD is uniquely suited to help evaluate the depth of treatment response.

With data already demonstrating the role of MRD for CLL response assessment and prognosis, cancer programs should prepare themselves for implementation of MRD testing for appropriate patients.

March is Multiple Myeloma Awareness Month. Learn how ACCC is supporting collaboration among healthcare providers with practical, scalable solutions to the real-world challenges of improving quality care delivery for patients with multiple myeloma.

In launching its new campaign, Transforming Complex To Clear, ACCC brought together expert panelists to discuss effective practices and offer tips to address current barriers to biomarker testing in the community setting.

Liquid biopsy, a genetic test that can eliminate some of the most serious potential drawbacks of traditional tissue biopsy, is gaining more traction in cancer care. But there remain significant barriers to its widespread use.

Led by the Prevent Cancer Foundation, ACCC has joined more than 300 organizations in signing a letter urging the passage of the MCED Screening Coverage Act, which will help cancer care providers be able to use the latest testing technologies to improve quality of life and better patient outcomes.